Veradermics (MANE) Retained Earnings (2025 - 2026)

Veradermics (MANE) reported Retained Earnings of -$150.7 million for Q1 2026, down 22.1% quarter-over-quarter from -$123.4 million in Q4 2025.

Veradermics (MANE) Retained Earnings (2025 - 2026) Analysis & Trends

Veradermics has reported Retained Earnings for 2 years, with the latest figure at -$150.7 million in Q1 2026.

  • For the quarter ending Q1 2026, Retained Earnings changed N/A year-over-year to -$150.7 million; the trailing twelve-month figure through Mar 2026 stood at -$150.7 million (changed N/A YoY), and the FY2025 full-year result was -$123.4 million, changed N/A from the prior year.
  • Retained Earnings for Q1 2026 stood at -$150.7 million, down from -$123.4 million in the prior quarter.
  • The five-year high for Retained Earnings was -$123.4 million in Q4 2025, with the low at -$150.7 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Retained Earnings (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -153.89 Mn
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -211.85 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 1.00 Bn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - 130.89 Mn
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -279.00 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -1.88
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 14.59 Bn
9 Abivax 91.96 Bn 91.96 Bn - -838.07 Mn
10 Veradermics 2.13 Bn 2.13 Bn - -150.70 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -150.70 Mn
Dec 31, 2025 -123.42 Mn